JVJames D. Vasta

James D. Vasta

*This is an algorithmically generated author record based on publicly available information.

James D. Vasta has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Denaturation-sensitive BRET probes enable intracellular thermal shift measurements across diverse protein targets and biomolecular complexes

    by James D. Vasta, Ani Michaud, Michael T. Beck, Inhong Hwang, Ashley Schwarzenstein, Cesear R. Corona, Paula Sequeira, Cara Happe, Martin P. Schwalm, Bryan Gehrke, et al.

    Thermal shift assays have revolutionized drug discovery, but can be limited in sensitivity and scalability. Combining the unique attributes of differential scanning fluorimetry (DSF) and cellular thermal shift (CETSA), we report the methodological framework for the bioluminescence resonance energy transfer shift assay (BRETSA). BRETSA utilizes denaturation sensitive BRET probes, in combination with luciferase-tagged target proteins, to track and longitudinally record thermal shift in living cells. Denaturation profiles were successfully measured for over 500 globular proteins, spanning 24 target families in diverse cellular compartments. Among these, target engagement was confirmed for over 200 proteins; including validated drug targets as well as understudied members of the kinase subfamily. Leveraging orthosteric, allosteric, and covalent ligands in potency studies, this method offers improved sensitivity and scalability compared to other thermal shift methods. We extend the utility of BRETSA to interrogate target engagement at biomolecular complexes and query cooperative binding for molecular glues and emerging tricomplex drug modalities.

  • Top Cited Papers

    Advances in BRET probes for intracellular target engagement studies

    by Jacob L. Capener, Martin P. Schwalm, James D. Vasta, Ani Michaud, Kelly A. Teske, William M. Marsiglia, Kilian V. M. Huber, Arvin C. Dar, Stefan Knapp, Alison D. Axtman, et al.

    Assessing drug-target engagement in living cells is essential for verifying the activity of pharmacological agents. Traditional binding assays often overlook key factors such as permeability, intracellular distribution and complex formation that influence target occupancy in cells. Bioluminescence resonance energy transfer (BRET)-based probes enable direct, quantitative assessment of small-molecule binding to proteins in live, intact cells. BRET provides sensitive detection of target engagement across a wide range of target classes, including less-tractable proteins in membrane compartments. Compared to other existing methods, BRET offers quantification of drug occupancy at steady state and open system regimens. Recent innovations in this platform have expanded its utility beyond occupancy confirmation to include applications in polypharmacology and mechanism-of-action studies. Here, we provide an updated perspective on BRET target engagement assays as versatile tools for chemical biology and early-stage drug discovery.


  • Open Access

    Development of SYK NanoBRET Cellular Target Engagement Assays for Gain–of–Function Variants

    by Jacob L. Capener, James D. Vasta, Vittorio L. Katis, Ani Michaud, Michael T. Beck, Sabrina C. D. Daglish, Sarit Cohen-Kedar, Efrat Shaham Barda, Stefanie Howell, Iris Dotan, et al.

    Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase that is activated by phosphorylation events downstream of FcR, B-cell and T-cell receptors, integrins, and C-type lectin receptors. When the tandem Src homology 2 (SH2) domains of SYK bind to phosphorylated immunoreceptor tyrosine-based activation motifs (pITAMs) contained within these immunoreceptors, or when SYK is phosphorylated in interdomain regions A and B, SYK is activated. SYK gain-of-function (GoF) variants were previously identified in six patients that had higher levels of phosphorylated SYK and phosphorylated downstream proteins JNK and ERK. Furthermore, the increased SYK activation resulted in the clinical manifestation of immune dysregulation, organ inflammation, and a predisposition for lymphoma. The knowledge that the SYK GoF variants have enhanced activity was leveraged to develop a SYK NanoBRET cellular target engagement assay in intact live cells with constructs for the SYK GoF variants. Herein, we developed a potent SYK-targeted NanoBRET tracer using a SYK donated chemical probe, MRL-SYKi, that enabled a NanoBRET cellular target engagement assay for SYK GoF variants, SYK(S550Y), SYK(S550F), and SYK(P342T). We determined that ATP-competitive SYK inhibitors bind potently to these SYK variants in intact live cells. Additionally, we demonstrated that MRL-SYKi can effectively reduce the catalytic activity of SYK variants, and the phosphorylation levels of SYK(S550Y) in an epithelial cell line (SW480) stably expressing SYK(S550Y).

  • Open Access

    Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells

    by Xuan Yang, Jeffery L Smith, Michael T Beck, Jennifer M Wilkinson, Ani Michaud, James D. Vasta, Matthew B. Robers, Timothy M. Willson

    PLK1 is a protein kinase that regulates mitosis and is both an important oncology drug target and a potential anti target of drugs for the DNA damage response pathway or anti-infective host kinases. To expand the range of live cell NanoBRET target engagement assays to include PLK1 we developed an energy transfer probe based on the anilino-tetrahydropteridine chemotype found in several selective PLK inhibitors. Probe 11 was used to configure NanoBRET target engagement assays for PLK1, PLK2, and PLK3 and measure the potency of several known PLK inhibitors. In cell target engagement for PLK1 was in good agreement with the reported cellular potency for inhibition of cell proliferation. Probe 11 enabled investigation of the promiscuity of adavosertib, which had been described as a dual PLK1/WEE1 inhibitor in biochemical assays. Live cell target engagement analysis of adavosertib by NanoBRET demonstrated PLK activity at micromolar concentrations but only selective engagement of WEE1 at clinically relevant doses.


  • Open Access

    KRAS is vulnerable to reversible switch-II pocket engagement in cells

    by James D. Vasta, D. Matthew Peacock, Qinheng Zheng, Joel A. Walker, Ziyang Zhang, Chad A. Zimprich, Morgan R. Thomas, Michael T. Beck, Brock F. Binkowski, Cesear R. Corona, et al.

    Current small-molecule inhibitors of KRAS(G12C) bind irreversibly in the switch-II pocket (SII-P), exploiting the strong nucleophilicity of the acquired cysteine as well as the preponderance of the GDP-bound form of this mutant. Nevertheless, many oncogenic KRAS mutants lack these two features, and it remains unknown whether targeting the SII-P is a practical therapeutic approach for KRAS mutants beyond G12C. Here we use NMR spectroscopy and a cellular KRAS engagement assay to address this question by examining a collection of SII-P ligands from the literature and from our own laboratory. We show that the SII-Ps of many KRAS hotspot (G12, G13, Q61) mutants are accessible using noncovalent ligands, and that this accessibility is not necessarily coupled to the GDP state of KRAS. The results we describe here emphasize the SII-P as a privileged drug-binding site on KRAS and unveil new therapeutic opportunities in RAS-driven cancer.


  • Open Access

    Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation

    by Kristin M. Riching, James D. Vasta, Scott J. Hughes, Vittoria Zoppi, Chiara Maniaci, Andrea Testa, Marjeta Urh, Alessio Ciulli, Danette L. Daniels